DR-70 testAn ELISA assay that quantifies fibrin and fibrinogen degradation products in blood, which are increased in various cancers and further increase as the malignancy grows. DR-70 screening is FDA-approved for lung, breast, stomach, liver, colorectal, ovarian, oesophageal, cervical, trophoblastic, thyroid, brain and pancreatic cancers, as well as lymphoma, and may be better at detecting recurrent colorectal cancer than the time-honoured measurement of CEA levels.
DR-70 is increased after surgery, chemotherapy and radiotherapy.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.